USPTO serial 79326861
BIOTEST
Reviewed by CopyMark Law Group
Status 405
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BIOTEST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John W. McGlynn
John W. McGlynn RatnerPrestia2200 Renaissance Blvd, Suite 350King of Prussia, PA 19406UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry and science, namely, proteins and protein preparations made from human blood, blood plasma or blood serum, in particular human albumin, coagulation factors and immunoglobulins; recombinant proteins; plasma fractions; excipients for the stabilization of medicines, in particular human albumin; excipients for the stabilization of medicines, in particular human albumin | SECTION 70 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; human albumin, coagulation factors and coagulation inhibitors, in particular factor VIII, factor IX, factor X, fibrinogen; immunoglobulin preparations, immunoglobulins and hyperimmunoglobulins; recombinant proteins, in particular coagulation factors and monoclonal antibodies; pharmaceutical products for haematology, immunology, neurology, intensive medicine, transplantation medicine, oncology; pharmaceutical products for preventing and treating viral diseases, for treating diseases of the immune system, for treating autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiallergic, hyposensitizing and detoxifying or toxine-neutralizing medicines | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 22, 2022 | TRPT | REQUEST FOR TRANSFORMATION PROCESSED - TOTAL | — |
| Jun 17, 2022 | ERFT | TEAS REQUEST FOR TRANSFORMATION RECEIVED | — |
| Apr 10, 2022 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Apr 9, 2022 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Dec 17, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 13, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 8, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 25, 2021 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |